Measuring health-related quality of life in women on hormone replacement therapy

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 3, 2003, Pages 351-361

  Sintonen, Harri ^a   Johansson, Stiina ^d   Ohinmaa, Arto ^b   Apajasalo, Marjo ^d   Kainulainen, Petri ^d   Heikkinen, Jorma ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF ALBERTA   (Canada)

^c OULU DEACONESS INSTITUTE   (Finland)

^d NONE

Author keywords

15D; Estradiol valerate plus medroxyprogesterone acetate; Hormone replacement therapy; Nottingham Health Profile (NHP); Quality of life; Quality of life measures

Indexed keywords

CHLORMADINONE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; INDIVINA; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE;

ADULT; AGED; BREATHING; CONTROLLED STUDY; COST UTILITY ANALYSIS; DEPRESSION; EMOTION; EMOTIONAL STRESS; FEEDING BEHAVIOR; FEMALE; HEARING; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MENOPAUSAL SYNDROME; MENTAL FUNCTION; MOBILIZATION; OSTEOPOROSIS; PAIN ASSESSMENT; PHYSICAL ACTIVITY; QUALITY OF LIFE; RATING SCALE; REVIEW; SEXUAL BEHAVIOR; SLEEP; SOCIAL ISOLATION; SPEECH; TREATMENT OUTCOME; VISION; WELLBEING;

EID: 0038341664     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.3.351     Document Type: Review

References (60)

1. Zichella L. Clinical management of the menopausal woman. Int. J. Fertil. Menopausal Stud. 38(Supp.1), 15-22 (1993).
2. Oldenhave A, Netelenbos C. Pathogenesis of climacteric complaints: ready for the change? Lancet 343(8898), 649-653 (1994).
3. Compston JE. Osteoporosis. Clin. Endocrinol. 33(5), 653-.682 (1990).
4. Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada CMAJ 167(Suppl. 10), S1-S34 (2002).
5. Mattsson LA, Samsioe G. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen. Acta Obstet. Gynecol. Scand. Suppl. 130, 53-58 (1985).
6. Persson I, Adami HO, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Brit. Med. J. 298(6667), 147-151 (1989).
7. Marsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 4(2), 95-102 (1982).
8. MacKeigan LD, Pathak DS. Overview of health-related quality-of-life measures. Am. J. Hosp. Pharm. 49, 2236-2245 (1992).
9. World Health Organization. Constitution of the World Health Organization, Annex 1. In: The First Ten Years of the World Health Organization. World Health Organization, Geneva, Switzerland (1958).
10. Schipper H, Clinch JJ, Olweny CLM. Quality of Life Studies: Definitions and Conceptual Issues. In: Quality of Life and Pharmacoeconomics in Clinical Trials. Spilker B (Ed.). Lippincott-Raven Publishers, Philadelphia, PA, USA 11-23 (1996).
11. Olschewski M, Schulgen G, Schumacher M, Altman DG. Qaafiry of life assessment in clinical cancer research. Brit. J. Cancer 70, 1-5 (1994).
12. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann. Intern. Med. 118, 622-629 (1993).
13. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann. Med. 33(5), 337-343 (2001).
14. Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham. Health Profile: subjective health status and medical consultations. Soc Sci Med. A. 15(3 Pt 1), 221-229 (1981).
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30(6), 473-483 (1992).
16. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19(8), 787-805 (1981).
17. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann. Med. 33(5), 375-384 (2001).
18. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann. Med. 33(5), 328-336 (2001).
19. Guyatt GH, Jaeschke RJ. Reassessing quality-of-life instruments in the evaluation of new drugs. PhamacoEconomics. 12(6), 621-626 (1997).
20. Kaplan RM, Anderson JP. A general health policy model: update and application. Health Serv. Res. 23, 203-235 (1988).
21. Martinez-Martin P. Health-related quality of life in Parkinson's disease: outcomes of the therapeutic interventions. Expert Rev. Pharmacoeconomics Outcomes Res. 1, 99-108 (2001).
22. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. J. Am. Med. Assoc. 272, 619-626 (1994).
23. Jolicoeur LM, Jones-Grizzle AJ, Boyle JG. Guidelines for performing a pharmacoeconomic analysis. Am. J. Hosp. Pharm. 49, 1741-1747 (1992).
24. Brooks R, with the EuroQol Group. EuroQol: the current state of play. Health Policy 37, 53-72 (1996).
25. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual. Life Res. 8(3), 209-224 (1999).
26. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J. Clin. Epidemiol. 51(11), 1115-1128 (1998).
27. Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychology Health 7, 45-54 (1992).
28. Ryan N, Rosner A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clin. Ther. 23(7), 1099-1115 (2001).
29. Voss S, Quail D, Dawson A et al. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 109(8), 874-885 (2002).
30. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study, Am. J. Obstet. Gynecol. 168(3 Pt 1), 824-830 (1993).
31. Limouzin-Lamothe MA, Mairon N, Joyce CF, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am. J. Obstet. Gynecol. 170(2), 618-624 (1994).
32. Karlberg J, Martsson LA, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstet. Gynecol. Scand. 74(5), 367-372 (1995).
33. Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet. Gynecol. 96(3), 359-365 (2000).
34. Genazzani AR. Nicolucci A, Campagnoli C et al. Assessment of the QOL in Italian menopausal women: comparison between HRT users and nonusers. Maturitas 42(4), 267-280 (2002).
35. Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 14(3), 225-236 (1992).
36. Fitzpatrick LA, Pace C, Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J. Womens Health Gend. Based Med. 9(4), 381-387 (2000).
37. Ulrich LG, Barlow DH, Sturdee DW et al. Quality of life and patient preference for sequential versus continuous combined HRT. the UK Kliofem multicenter study experience. Int. J. Gynaecol. Obstet. 59(Suppl. 1), S11-S17 (1997).
38. Huber J, Palacios S, Berglund L et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 109(8), 886-893 (2002).
39. Wiklund I, Holst J, Karlberg J et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 14(3), 211-224 (1992).
40. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. Brit. Med. J. 307(6908), 836-840 (1993).
41. Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Brit. J. Obstet. Gynaecol. 104(10), 1191-1195 (1997).
42. Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 4(4), 314-319 (2001).
43. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287(5), 591-597 (2002).
44. Heikkinen JE, Vaheri RT, Ahomaki SM, Kainulainen PM, Viitanen AT, Timonen UM. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am. J. Obstet. Gynecol. 182(3), 560-567 (2000).
45. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestine regimens. Osteoporos. Int. 11(11), 929-937 (2000).
46. Stavem K. Reliability, validity and responsiveness of two multi attribute utility measures in patients with chronic obstructive pulmonary disease. Quality of Life Research 8(1-2), 45-54 (1999).
47. Rissanen P, Sogaard J, Sintonen H. Do QOL instruments agree? A comparison of the 15D and NHP in hip and knee replacements. Int. J. Technol. Assess Healthcare 16(2), 696-705 (2000).
48. Malmivaara A, Hakkinen U, Aro T et al. The treatment of acute low back pain-bed rest, exercises, or ordinary activity? N. Engl. J. Med. 332(6), 351-355 (1995).
49. Kauppinen R, Sintonen H, Tukiainen H. One-year economic evaluation of intensive versus conventional patient education and supervision for self-management of new asthmatic patients. Respir. Med. 92(2), 300-307 (1998).
50. Wiklund I, Karlberg J. Evaluation of quality of life in clinical trials. Selecting quality-of-life measures. Controlled Clinical Trials. 12(Suppl), 204-216 (1991).
51. Koivukangas P, Ohinmaa A. Koivukangas J. Nottingham Health Profilen (NHP) suomalainen versio. STAKES, Report No. 187, Helsinki, Finland 1-87 (1995).
52. Arinen S, Hakkinen U, Klaukka T, Klavus J, Lehtonen R, Aro S. Health and the use of health services in Finland. Main findings of the Finnish Healthcare Survey 1995/96 and changes from 1987. Official Statistics of Finland, Helsinki, Finland (1998).
53. Kauppinen P, Sintonen H, Vilkka V, Pekurinen M, Tukiainen H. Quality-of-life measures and clinical parameters in asthmatics during three year follow-up. Monaldi. Arch. Chest Dis. 53(4), 400-404 (1998).
54. Hyland ME. The validity of health assessments: resolving some recent differences. J. Clin. Epidemiology 46, 1019-1023 (1993).
55. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. Oxford University Press, Oxford (UK), NY (USA), Tokyo (Japan) (1989).
56. Juniper EF, Guyatt GH, Jaeschke R. How to Develop and Validate a New Health-Related Quality of Life Instrument. In: Quality of Life and Pharmacoeconomics in Clinical Trials. Spilker B (Ed.). Lippincort-Raven Publishers, PA. USA 49-56 (1996).
57. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J. Chronic Dis. 38(1), 27-36 (1985).
58. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision-making. In: Quality of Life Assessment in Clinical Trials. Spilker B (Ed.). Raven Press, NY, USA 11-63 (1993).
59. Sintonen H. Outcome measurement in acid-related disease. PharmacoEconomics 5(Suppl. 3), 17-26 (1994).
60. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. Oxford University Press, NY, USA (1987)